NeuBase Therapeutics, Inc. (NBSE): Price and Financial Metrics
GET POWR RATINGS... FREE!
NBSE Stock Price Chart Interactive Chart >
NBSE Price/Volume Stats
| Current price | $0.24 | 52-week high | $2.08 |
| Prev. close | $0.25 | 52-week low | $0.17 |
| Day low | $0.24 | Volume | 97,600 |
| Day high | $0.25 | Avg. volume | 306,694 |
| 50-day MA | $0.23 | Dividend yield | N/A |
| 200-day MA | $0.67 | Market Cap | 7.88M |
NeuBase Therapeutics, Inc. (NBSE) Company Bio
NeuBase Therapeutics, Inc. produces and distributes pharmaceutical products. The Company offers drugs for the treatment of dominant genetic disorders and oncogenic mutations causing cancers. NeuBase Therapeutics serves patients in the United States.
Latest NBSE News From Around the Web
Below are the latest news stories about NEUBASE THERAPEUTICS INC that investors may wish to consider to help them evaluate NBSE as an investment opportunity.
NeuBase Therapeutics selling stake in company to New York investment firm Alumni CapitalNeuBase specializes in genetic medicine therapies that target disease-triggering DNA and RNA mutations. |
Have you been able to find a good deal on NeuBase Therapeutics Inc.’s shares?NeuBase Therapeutics Inc. (NASDAQ:NBSE) marked $0.22 per share on Friday, up from a previous closing price of $0.21. While NeuBase Therapeutics Inc. has overperformed by 4.79%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NBSE fell by -92.71%, with highs and lows ranging from $3.18 to […] |
NeuBase Therapeutics GAAP EPS of -$1.04 beats by $0.04NeuBase Therapeutics press release (NBSE): FY GAAP EPS of -$1.04 beats by $0.04.As of September 30, 2022, the Company had cash and cash equivalents of approximately $23.2… |
NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2022PITTSBURGH, Dec. 21, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today reported its financial results for the fiscal year ended September 30, 2022, and other recent developments. “Fiscal year 2022 was a challenging period in our Company’s history as we faced a tightening of the broader capital markets for |
NeuBase Therapeutics Inc. (NASDAQ:NBSE) Share Price Recovers 25.0% From Its Lows, But Can It Maintain Its Rise?In last trading session, NeuBase Therapeutics Inc. (NASDAQ:NBSE) saw 0.13 million shares changing hands with its beta currently measuring 0.82. Company’s recent per share price level of $0.24 trading at $0.01 or 4.16% at ring of the bell on the day assigns it a market valuation of $8.25M. That closing price of NBSE’s stock is … NeuBase Therapeutics Inc. (NASDAQ:NBSE) Share Price Recovers 25.0% From Its Lows, But Can It Maintain Its Rise? Read More » |
NBSE Price Returns
| 1-mo | 15.94% |
| 3-mo | -14.29% |
| 6-mo | -78.18% |
| 1-year | -82.48% |
| 3-year | -96.50% |
| 5-year | -96.36% |
| YTD | 26.18% |
| 2022 | -93.23% |
| 2021 | -59.80% |
| 2020 | -2.92% |
| 2019 | 300.00% |
| 2018 | -95.16% |
Loading social stream, please wait...